NeutriSci International and Lexaria Bioscience are pleased to announce the successful development and initial trial of the industry's first cannabinoid/pterostilbene edible tablet utilising NeutriSci's and Lexaria's proprietary and patented technologies.
NeutriSci's proprietary pterostilbene tablet formula and Lexaria's technology were combined to produce the first market ready pterostilbene/cannabidiol (CBD) rapid melt edible product.
The pretrial hypothesis focused on whether the combination of NeutriSci's patented pterostilbene formula and Lexaria's patented CBD conjugation would prove effective in rapidity of onset, and strength of effect, while delivering improvements in taste.
These initial trial results have demonstrated that the consumer experiences positive effects that occur more immediately, and last longer, while utilising dose-controlled amounts of CBD.
Based on these positive results, NeutriSci and Lexaria will formalise the JV agreement to market and commercialise a line of edible products using CBD derived from full spectrum hemp oil, which is legal throughout the United States, along with several tetrahydrocannabinol (THC) versions through distribution programmes with both existing and new strategic partners.
"We are very pleased with the results of this observational trial, as the initial results have been invaluable in helping NeutriSci open dialogue with several of the world's largest CBD manufacturers and distributors," commented Glen Rehman, President of NeutriSci.
"The idea of using our sublingual tablet and form factor to create a new line of zero-sugar and dose-controlled cannabinoid edible products will become a reality. This new ground breaking proprietary tablet and form factor addresses what manufacturers, distributors and consumers have been asking, and positions us to be an industry leader in what will be a multi-billion-dollar industry."
"This JV is a demonstration of the rapid innovation occurring in the cannabis industry," commented Chris Bunka, CEO of Lexaria Bioscience. "We are excited to work with NeutriSci; using both company's technologies, ingredients and form factor to develop healthy cannabinoid products."
